Study of lademirsen (SAR339375) in patients with Alport Syndrome
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients with Alport Syndrome - HERA A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Phar ...
Congenital, hereditary and neonatal diseases MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Congenital, hereditary and neonatal diseases MedDRA version: 20.0;Level: PT;Classification code 1000 ...
Product Name: Lademirsen Product Code: SAR339375 Other descriptive name: RG-012
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Phar ...
Alport's Syndrome
Drug: lademirsen (SAR339375);Drug: Placebo
Genzyme, a Sanofi Company
NULL
Terminated
18 Years
55 Years
All
43
Phase 2
United States;Australia;China;France;Germany;Spain;United Kingdom;Canada